[{"id":"5444acae-553a-425f-a15f-fcc1a2b42abb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02826434","created_at":"2021-01-18T13:51:30.016Z","updated_at":"2025-02-25T15:07:08.523Z","phase":"Phase 1","brief_title":"Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer","source_id_and_acronym":"NCT02826434","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-09-23"},{"id":"b1b3d9cc-183d-4233-8eed-c61644ce67f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03362060","created_at":"2021-01-18T16:35:42.711Z","updated_at":"2025-02-25T16:07:16.873Z","phase":"Phase 1","brief_title":"PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03362060","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PVX-410"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-09-23"},{"id":"167a4ae9-d051-47bd-af76-6495f94636e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634747","created_at":"2021-01-19T20:37:14.629Z","updated_at":"2024-07-02T16:36:11.770Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04634747","lead_sponsor":"OncoPep, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • HLA-A2 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • PVX-410"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 04/30/2022","start_date":" 04/30/2022","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2022-04-20"}]